These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34266917)

  • 1. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Grothe MJ; Moscoso A; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Snellman A; Zetterberg H; Blennow K; Schöll M;
    Neurology; 2021 Sep; 97(12):e1229-e1242. PubMed ID: 34266917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
    Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.
    Asken BM; Tanner JA; VandeVrede L; Mantyh WG; Casaletto KB; Staffaroni AM; La Joie R; Iaccarino L; Soleimani-Meigooni D; Rojas JC; Gardner RC; Miller BL; Grinberg LT; Boxer AL; Kramer JH; Rabinovici GD
    Neurology; 2022 Aug; 99(6):e594-e604. PubMed ID: 35577574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
    Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
    Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.
    Kurihara M; Matsubara T; Morimoto S; Arakawa A; Ohse K; Kanemaru K; Iwata A; Murayama S; Saito Y
    Acta Neuropathol Commun; 2024 Mar; 12(1):48. PubMed ID: 38539238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy.
    Wang ZB; Tan L; Gao PY; Ma YH; Fu Y; Sun Y; Yu JT;
    Alzheimers Dement; 2023 Oct; 19(10):4421-4435. PubMed ID: 37506291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy.
    Wang ZB; Tan L; Wang HF; Chen SD; Fu Y; Gao PY; Ma YH; Guo Y; Hou JH; Zhang DD; Yu JT;
    Alzheimers Dement; 2023 Aug; 19(8):3613-3624. PubMed ID: 36840620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change.
    Bermudez C; Graff-Radford J; Syrjanen JA; Stricker NH; Algeciras-Schimnich A; Kouri N; Kremers WK; Petersen RC; Jack CR; Knopman DS; Dickson DW; Nguyen AT; Reichard RR; Murray ME; Mielke MM; Vemuri P
    Acta Neuropathol; 2023 Jul; 146(1):13-29. PubMed ID: 37269398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology.
    Cousins KAQ; Arezoumandan S; Shellikeri S; Ohm D; Shaw LM; Grossman M; Wolk D; McMillan CT; Chen-Plotkin A; Lee E; Trojanowski JQ; Zetterberg H; Blennow K; Irwin DJ
    Neurology; 2022 Nov; 99(20):e2303-e2312. PubMed ID: 36041863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
    Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.
    Morrison MS; Aparicio HJ; Blennow K; Zetterberg H; Ashton NJ; Karikari TK; Tripodis Y; Martin B; Palmisano JN; Sugarman MA; Frank B; Steinberg EG; Turk KW; Budson AE; Au R; Goldstein LE; Jun GR; Kowall NW; Killiany R; Qiu WQ; Stern RA; Mez J; McKee AC; Stein TD; Alosco ML
    Brain; 2022 Oct; 145(10):3546-3557. PubMed ID: 35554506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
    Leuzy A; Mattsson-Carlgren N; Cullen NC; Stomrud E; Palmqvist S; La Joie R; Iaccarino L; Zetterberg H; Rabinovici G; Blennow K; Janelidze S; Hansson O
    Alzheimers Dement; 2023 Jul; 19(7):2994-3004. PubMed ID: 36681387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
    Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.